Follow The Filings

ABBV AbbVie

Health Care, filed as ABBVIE INC (COM), Equity As of 2026 Q3 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2, sold by 5

  • 4 Owners
  • #79
  • Max 2.9%
  • Master 0.01%
  • $33M
  • 1 add 3 reduce

In 2026 Q3 Torray Investment Partners added to AbbVie, while David Katz, Kentucky Trust, and Murphy Pohlad trimmed.

Who owns this now

Largest portfolio weights among holders, up to 2.9% (Torray Investment Partners). Not free-float ownership.

  1. Torray Investment Partners Add 2.9%
  2. David Katz Reduce 0.73%
  3. Kentucky Trust Co. Reduce 0.70%
  4. Murphy Pohlad Reduce 0.30%

Who owns ABBV

Sorted by value, long equity only, as of 2026 Q3.

History
Torray Investment Partners 2.9%, was 2.8% Add +0.9% 83,376 $22M History
David Katz, Matrix Asset Advisors 0.73%, was 0.80% Reduce −13.2% 33,896 $8.9M History
Kentucky Trust Co., Kentucky Trust 0.70% Reduce −0.9% 5,319 $1.4M History
Murphy Pohlad, Murphy Pohlad Asset Management 0.30%, was 0.32% Reduce −8.6% 3,286 $860K History

4 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by ABBV's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ABBV insider trades
  • None no insider bought on the open market
  • $8.2M sold by 1 insider outside a trading plan
  • None no planned (10b5-1) sales
  1. Nicholas Donoghoe EVP, Chief Bus/Strat Officer
    Sale
    $8.2M 32,710 shares at $250.00 31% of stake
    Traded Aug 14 Filed Aug 18
    ↗

Also filed in the last 12 months, not counted as buying or selling: 11 stock grants and 1 option exercise.

Congress

18 members of Congress traded ABBV in the last three years: 25 buys and 23 sales. 26 members listed it in 2025 annual reports.

All Congress trades
  1. Pete Sessions R-TX-17 Sell $15K–$50K Sep 14 filed Sep 18
  2. Alan Armstrong R-OK Buy $15K–$50K Mar 27 filed Jul 21
  3. Josh Gottheimer D-NJ-5Joint Sell $1K–$15K May 5 filed Jun 3
  4. Julie Johnson D-TX-32Joint Sell $1K–$15K Dec 18, 2025 filed Jan 15
  5. Julia Letlow R-LA-5 Sell $1K–$15K Dec 8, 2025 filed Jan 13
  6. Julia Letlow R-LA-5 Buy $1K–$15K Apr 28, 2025 filed Jan 13

SEC filings

Recent issuer filings from EDGAR, 20 shown.

Filed Form Detail Links
8-K 2.02,9.01 Filing Doc
8-K 5.02 Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
424B5 Filing Doc
8-K 8.01,9.01 Filing Doc
424B5 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 5.07 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc

Source: SEC EDGAR submissions, updated about 2 hours ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $54.32B $56.33B $61.16B
Gross profit * $33.9B $39.43B $42.96B
Gross margin * 62.4% 70.0% 70.2%
Net income $4.86B $4.28B $4.23B
Net margin * 9.0% 7.6% 6.9%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $33B $25.58B $29.06B
Total non-current assets * $101.71B $109.58B $104.9B
Total assets $134.71B $135.16B $133.96B
Total current liabilities $37.84B $38.75B $43.29B
Total equity $10.36B $3.32B -$3.27B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $22.84B $18.81B $19.03B
Cash from investing -$2.01B -$20.82B -$6.64B
Cash from financing -$17.22B -$5.21B -$12.72B
Net change in cash $3.61B -$7.29B -$0.295B

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.